PLUR logo

PLURI INC

PLURNASDAQ
🏆 #4741 by market capEarnings Nov 5US Equity
$1.31▲ $0.11 (+9.62%)
Market closed · at close
🔔
Track PLUR
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 9.6%
7d▲ 50.6%
14d▲ 23.6%
30d▲ 23.6%
ytd▼ 56.5%
1y▼ 66.5%
🏦Market Cap
$14M
Small Cap
📈Revenue Growth (YoY)
-23.9%
Declining
📊Gross Margin
44.6%
Healthy
💵FCF Margin
-1990.3%
Thin
⚖️P/S Ratio
13.1x
Elevated
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.28 – $1.40
52-Week Range
$0.85 – $4.87
Volume (shares)
2,551
Avg Volume (shares)
—
Shares Outstanding
10.8M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$335,000
P/E Ratio
-0.5
P/S Ratio
13.1x
EPS (TTM)
$-2.26
Dividend Yield
0.00%
Dilution (1yr)
+16.9%
PLUR logo

PLURI INC

PLUR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▼ −24.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
44.6%▼ −8.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$25M▲ +12.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▲ +2.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.8M▲ +16.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$31M▲ +$4M YoY
StockOtter · stockotter.space

About PLURI INC

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

News unavailable.